Published in

Oxford University Press (OUP), Clinical Infectious Diseases, 8(69), p. 1440-1442, 2019

DOI: 10.1093/cid/ciz122

Links

Tools

Export citation

Search in Google Scholar

Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon

Journal article published in 2019 by Jose Diego Brito-Sousa ORCID, Thalie C. Santos, Sara Avalos, Gustavo Fontecha, Gisely C. Melo, Fernando Val ORCID, André M. Siqueira ORCID, Graça C. Alecrim, Quique Bassat, Marcus V. G. Lacerda, Wuelton M. Monteiro
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Despite glucose-6-phosphate dehydrogenase (G6PD) deficiency prevalence of 5% in the Amazon, primaquine is administered without G6PD screening. This is an important cause of hospitalization among Plasmodium vivax–infected individuals, leading to life-threatening anemia and acute renal failure across endemic areas. In Manaus, the frequency of primaquine-induced hemolysis was 85.2 cases per 100 000 primaquine users.